- Home
- TSHA vs INVA Comparison
TSHA vs INVA Comparison
Compare TSHA & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | INVA |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TSHA | INVA |
|---|---|---|
| Price | $4.38 | $20.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | $13.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 3.2M | 851.1K |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.56 | ★ 816.67 |
| EPS | N/A | ★ 1.25 |
| Revenue | $9,773,000.00 | ★ $217,217,000.00 |
| Revenue This Year | N/A | $9.72 |
| Revenue Next Year | $1,023.00 | $8.58 |
| P/E Ratio | ★ N/A | $16.44 |
| Revenue Growth | 17.28 | ★ 62.63 |
| 52 Week Low | $3.69 | $16.52 |
| 52 Week High | $7.30 | $25.15 |
Technical Indicators
Market Signals| Indicator | TSHA | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 29.00 | 42.94 |
| Support Level | $4.37 | $20.39 |
| Resistance Level | $4.72 | $21.73 |
| Average True Range (ATR) | 0.26 | 0.49 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 1.38 | 23.36 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.